Mouse Models Reveal Role of T-Cytotoxic and T-Reg Cells in Immune Response to Influenza: Implications for Vaccine Design.
T-cell cytoxicity
epithelial proliferation
iBALT
influenza
influenza vaccination
mouse models
viral exanthema
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
11 01 2019
11 01 2019
Historique:
received:
14
11
2018
revised:
04
01
2019
accepted:
07
01
2019
entrez:
16
1
2019
pubmed:
16
1
2019
medline:
17
5
2019
Statut:
epublish
Résumé
Immunopathologic examination of the lungs of mouse models of experimental influenza virus infection provides new insights into the immune response in this disease. First, there is rapidly developing perivascular and peribronchial infiltration of the lung with T-cells. This is followed by invasion of T-cells into the bronchiolar epithelium, and separation of epithelial cells from each other and from the basement membrane leading to defoliation of the bronchial epithelium. The intraepithelial reaction may involve either CD8 or CD4 T-cytotoxic cells and is analogous to a viral exanthema of the skin, such as measles and smallpox, which occur when the immune response against these infections is activated and the infected cells are attacked by T-cytotoxic cells. Then there is formation of B-cell follicles adjacent to bronchi, i.e., induced bronchial associated lymphoid tissue (iBALT). iBALT reacts like the cortex of a lymph node and is a site for a local immune response not only to the original viral infection, but also related viral infections (heterologous immunity). Proliferation of Type II pneumocytes and/or terminal bronchial epithelial cells may extend into the adjacent lung leading to large zones filled with tumor-like epithelial cells. The effective killing of influenza virus infected epithelial cells by T-cytotoxic cells and induction of iBALT suggests that adding the induction of these components might greatly increase the efficacy of influenza vaccination.
Identifiants
pubmed: 30641955
pii: v11010052
doi: 10.3390/v11010052
pmc: PMC6356589
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Influenza Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Arch Immunol Ther Exp (Warsz). 2013 Oct;61(5):341-53
pubmed: 23708562
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):E2551-60
pubmed: 22927425
J Immunol Res. 2017;2017:6104054
pubmed: 28316998
Exp Pathol. 1984;25(4):223-31
pubmed: 6540714
Cytokine. 2008 Apr;42(1):62-70
pubmed: 18334301
Front Immunol. 2015 May 15;6:237
pubmed: 26029218
Chest. 1973 Apr;63(4):644-6
pubmed: 4695372
Clin Infect Dis. 2012 Jul;55(1):19-25
pubmed: 22441650
J Exp Med. 1941 Jan 1;73(1):43-55
pubmed: 19871064
Nat Med. 2010 May;16(5):558-64, 1p following 564
pubmed: 20436484
Nat Med. 2012 Jan 29;18(2):274-80
pubmed: 22286307
Am J Respir Cell Mol Biol. 2013 Apr;48(4):406-14
pubmed: 23371062
Vaccine. 2013 Jan 11;31(4):670-5
pubmed: 23200938
Cancer Res. 2012 May 1;72(9):2162-71
pubmed: 22549946
Nat Rev Immunol. 2012 Jan 20;12(2):136-48
pubmed: 22266691
Front Immunol. 2016 Jun 30;7:258
pubmed: 27446088
Trends Immunol. 2014 Aug;35(8):396-402
pubmed: 25043801
Pathobiology. 2000 Jan-Feb;68(1):1-8
pubmed: 10859525
J Immunol. 2017 Feb 1;198(3):1142-1155
pubmed: 28031335
Vaccine. 2003 Jun 20;21(21-22):2805-12
pubmed: 12798621
Front Immunol. 2017 Jan 23;8:19
pubmed: 28167943
Clin Infect Dis. 2011 Jan 1;52(1):1-7
pubmed: 21148512
J Exp Med. 1991 Oct 1;174(4):915-24
pubmed: 1655948
J Biomed Biotechnol. 2011;2011:939860
pubmed: 22007149
Virol J. 2011 Nov 04;8:505
pubmed: 22050764
Annu Rev Pathol. 2008;3:499-522
pubmed: 18039138
Adv Immunol. 2010;107:187-241
pubmed: 21034975
Lab Invest. 1963 Jan;12:119-29
pubmed: 13945441
Viruses. 2010;2(8):1530-1563
pubmed: 21442033
Pathogens. 2014 Oct 21;3(4):845-74
pubmed: 25436508
Front Immunol. 2017 Feb 23;8:194
pubmed: 28280496
J Exp Med. 2011 Aug 1;208(8):1621-34
pubmed: 21788409
PLoS One. 2012;7(10):e48322
pubmed: 23118984
J Clin Invest. 2012 Aug;122(8):2847-56
pubmed: 22820287
Front Immunol. 2018 Jul 02;9:1479
pubmed: 30013557
Lab Invest. 1994 Jan;70(1):6-22
pubmed: 8302019
Expert Rev Vaccines. 2009 Apr;8(4):447-54
pubmed: 19348560
J Infect Dis. 1949 Mar-Apr;84(2):153-68
pubmed: 18113780
Hum Pathol. 1994 Jan;25(1):47-53
pubmed: 8314260
J Immunol. 2009 Jun 15;182(12):7353-63
pubmed: 19494257
J Intern Med. 2011 May;269(5):507-18
pubmed: 21362069
J Immunol. 2013 Apr 1;190(7):3438-46
pubmed: 23467933
Vaccine. 2008 Sep 12;26 Suppl 4:D59-66
pubmed: 19230162
J Exp Med. 1931 Jul 31;54(3):349-59
pubmed: 19869922
Respir Res. 2009 Nov 12;10:107
pubmed: 19909524
Nat Med. 2004 Sep;10(9):927-34
pubmed: 15311275
Curr Protoc Microbiol. 2009 May;Chapter 15:Unit 15G.3
pubmed: 19412911
Proc Natl Acad Sci U S A. 1985 Mar;82(6):1785-9
pubmed: 3872457
J Histochem Cytochem. 1996 Feb;44(2):113-23
pubmed: 8609367
Proc Natl Acad Sci U S A. 1983 Dec;80(23):7155-9
pubmed: 6580632
Curr Opin Cell Biol. 2001 Oct;13(5):555-62
pubmed: 11544023
Viral Immunol. 2014 Dec;27(10):484-96
pubmed: 25479178
Am J Pathol. 1945 Nov;21(6):1121-41
pubmed: 19970853
Am J Pathol. 2003 Oct;163(4):1341-55
pubmed: 14507643
J Immunol. 2006 Sep 1;177(5):2888-98
pubmed: 16920924
J Virol. 2013 Dec;87(23):12636-47
pubmed: 24049180